ft

FGTI-2734 是 有效的RAS C-末端法尼基转移酶 (FT) 和香叶烯基转移酶-1 (GGT-1) 抑制剂，IC50s 分别为 250 nM 和 520 nM。 它可以阻断 KRAS 的膜定位，从而解决 KRAS 耐药性问题，并抑制突变的 KRAS 胰腺肿瘤。

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

FT001是一种有效的、选择性的和具有口服活性的 BET Bromodomain 抑制剂，具有抗肿瘤活性。FT001抑制 MYC 的表达，IC50为0.46 μM。FT001对 MV-4-11具有有效的抗增殖作用，并在体外和体内显著抑制 MYC mRNA 水平。

FT-1518 是一种可口服且具有选择和高效性的 mTORC1 和 mTORC2 抑制剂，具有抗癌抗肿瘤活性，可用于研究癌症。

FT895 是一种具有选择性和有效性的 HDAC11 抑制剂，具有抗真菌和抗肿瘤活性，抑制 HDAC11 表达，限制 EV71在体外复制。

(R)-FT671 is the R-isomer of FT671. FT671 is a potent, non-covalent and selective inhibitor of USP7 (IC50 of 52 nM)

FT827 是选择性泛素特异性蛋白酶 7（USP7）共价抑制剂（Ki=4.2 µM，Kd=7.8 μM），靶向 USP7 的自抑制载脂蛋白形式的催化中心,可用于研究癌症。

FT-FAPI-12_9 (TFA)为FAP结合物，主要应用于FAPI-46放射性示踪剂的合成。

FT-1101 is an oral bioavailable, effective and selective BET inhibitor.

FT206 is a carboxamide inhibitor of ubiquitin-specific protease[1].

Notoginsenoside Ft1 是一种植物分离的三七皂苷，具有刺激血管生成的作用。

FT385 is a novel USP30 inhibitor, recapitulating genetic loss of USP30 and setting the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation.

FT-1101 is an orally bioavailable, potent and selective BET inhibitor. FT-1101 binds to the acetylated lysine recognition motifs in the bromodomain sites of BET proteins, thereby preventing the interaction between the BET proteins and acetylated histones. This disrupts chromatin remodeling and gene expression. Prevention of the expression of certain growth-promoting genes may lead to the inhibition of tumor cell growth. BET proteins, comprised of BRD2, BRD3, BRD4 and BRDT, are transcriptional regulators that play an important role during development and cellular growth.

FT011 是抗纤维化剂，能够抑制胶原蛋白 I 和 III 的 mRNA 表达，减少胶原蛋白合成。

FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM).

FT113 是口服具有活力的脂肪酸合酶抑制剂，对全长重组人 FASN 酶的 IC50=213 nM。在 BT474 细胞中，它抑制 FASN 的特性，IC50=90 nM。它具有抗增殖作用，在体内和体外实验中，都具有抗癌作用。

FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC50s of 1.4 nM and 1.7 μM, respectively.

FTI-2148 is an inhibitor of RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) (IC50s: 1.4 nM and 1.7 μM, respectively).

FT3967385 is a newly developed compound that functions as a USP30 inhibitor, emulating the genetic deficiency of USP30. This inhibition serves as a catalyst for the amplification of mitochondrial ubiquitylation through the PINK1-PARKIN pathway.

FT709 是选择性的USP9X 有效抑制剂 (IC50: 82 nM)。其中USP9X 与中心体功能、EGF 受体降解、有丝分裂期间的染色体排列、化学致敏和昼夜节律有关。

(R)-FT709为活跃化合物，适用于癌症研究领域。

Pocenbrodib (FT-7051) 是一种有效的 CBP p300 家族的溴结构域抑制剂，具有潜在的抗肿瘤活性，可口用于研究癌症。

(Rac)-Etavopivat((Rac)-FT-4202) 是Etavopivat 异构体。Etavopivat 是一种具有口服活性的的红细胞丙酮酸激酶-R (PKR) 激活剂，可以用于镰状细胞病和其他血红蛋白疾病研究。

Tegafur (FT 207) 是一种前药，在肝脏中被细胞色素 P-450 酶逐渐转化为氟尿嘧啶。它是抗代谢物氟尿嘧啶的同源物，具有抗肿瘤活性。